Research and Science

20 Years of Human Neuroscience Research with Psychedelics

In 2025 it will be 20 years since the Centre for Psychedelic Research began its study of psychedelic drugs in humans, first at Bristol University and then since 2008 at Imperial College London. What started out as an imaging study of the brain mechanisms of psilocybin in collaboration with Robin Carhart-Harris and Amanda Feilding has turned into a life changing body of research that has encompassed many hundreds of colleagues: doctors psychologists and neuroscientists.

David Nutt

PS2023 Cannabis Health Conditions Psychedelic Assisted Therapy PTSD Research and Science Veterans

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind Study to Assess Safety/Efficacy of Inhaled Cannabis in Veterans for PTSD

Study aims to re-examine inhaled cannabis for treating PTSD, with Phase 2 study assessing high THC cannabis versus placebo for managing symptoms and pain in 360 veterans across U.S.

Sue Sisley, Shane Pennington

PS2023 Health Equity Integration Policy Psychedelic Assisted Therapy Public Benefit Research and Science

Building the next generation of psychedelic care clinics

Integration of psychedelic therapy into healthcare requires clinics to provide safe care. Planning infrastructure carefully, considering environmental factors, is crucial for successful delivery of psychedelic services.

Daniel Kelly, Gregory Kearns, Payton Nyquvest

PS2023 Business Policy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

Lessons from the first three years of psychedelic public companies

Psychedelic businesses have rapidly emerged on American and Canadian exchanges, creating a multibillion dollar market. Industry insiders discuss challenges and predictions for psychedelic public companies.

Patrick Trucchio, Florian Brand, George Tziras, Tim Chang

PS2023 Health Equity Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science

Achieving market access and reimbursement for psychedelic therapy

Panel experts discuss insurance coverage requirements for wide accessibility of psychedelic therapy, addressing what payors will need to support the treatments.

Elliot Marseille, Dan Grossman, Sherry Rais, Leslie Nylund

PS2023 Business Policy and Advocacy Psychedelic Science Research Research and Science

Regulatory considerations and opportunities

Panel on regulatory obstacles in psychedelic therapy research: Leaders from the industry discuss challenges with policymakers and predict future developments in the field.

Tadeusz Hawrot, Natasia Poinsatte, Nicole Howell

PS2023 Health Equity Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Group sessions can make psychedelic treatment more accessible: Empirical evidence

Dr. Smith and Dr. Jones analyze the economic impact of drug pricing and care costs on the psychedelic market at PS2023.

PS2023 Business Harm Reduction Policy and Advocacy Public Benefit Research and Science Social Justice

Growing up: The next cycle of venture funding for psychedelic companies

Commercial investment dominates psychedelic sector funding, primarily for drug discovery. Non-commercial projects need financial backing for drug policy reform, public health education, harm reduction, and diversity initiatives. Strategic funding can

Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen

PS2023 Business Policy and Advocacy Psychedelic Science Research Research and Science Social and Cultural

Patents, commons, and innovation in psychedelic drug development

Universities and companies are claiming intellectual property on psychedelic compounds, sparking dialogue on how patents may impact innovation and access to care in the psychedelic ecosystem. Explore economic and cultural

Jonathan Sporn, Sisi Li, Graham Pechenik, Retsina Meyer, Anne Donohoe

PS2023 Harm Reduction Health Equity Policy and Advocacy Psychedelic Assisted Therapy Research and Science Therapy Ethics

Telemedicine models for supporting psychedelic therapy

Panel explores how telemedicine can enhance psychedelic therapy practice, discussing benefits and risks of virtual care in light of pandemic-induced regulatory changes and improved meeting tech.

Juan Pablo Cappello, Jonathan Sabbagh